SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : The biotechnology mini portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (78)2/14/2007 1:07:42 PM
From: Mike McFarland  Read Replies (1) of 93
 
I sold 2175 shares of EXEL at $10.81

<Exelixis said it expects fiscal 2007 revenue in the range of
$120.0 million to $135.0 million and operating expenses of
$260.0 million to $290.0 million, including stock-based
compensation and other non-cash charges of about $20.0
million.>

I'd like to re-enter the shares a few bucks lower than
where the stock is trading right now. Greedy or squeamish,
call it what you will.

We have $23,500 cash earmarked for EXEL at a lower price,
we had a $4300 gain on that position.

I'm not asking for a motion to second that trade, but
if there are strong objections I will ask before making
future trades.

I am looking to sell MYGN at $35, sort of a stop loss
as the chart tops out. Anybody want to second that before
I sell it anyway? Our $10k speculation on MYGN shares
has gained $5k, not a bad trade and maybe worth locking it
in for awhile.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News